Premium
Dabigatran (Pradaxa) for stroke prevention in atrial fibrillation
Author(s) -
Chaplin Steve,
Lip Gregory
Publication year - 2012
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.927
Subject(s) - medicine , dabigatran , atrial fibrillation , stroke (engine) , cardiology , intensive care medicine , warfarin , mechanical engineering , engineering
Dabigatran (Pradaxa) is a new oral anticoagulant licensed for the prevention of stroke in patients with atrial fibrillation and a risk factor for stroke. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events compared with warfarin, and Professor Gregory Lip considers its potential role in therapy.